Moredun Scientific receives funding from Eurostars for further development of Streptococcus suis piglet vaccine

Moredun Scientific has been awarded funding through the Eurostars-2 program to collaborate with Swedish based Intervacc to support the further development of Intervacc`s innovative vaccine to protect piglets against infection caused by the bacterial pathogen Streptococcus suis.

The Eurostars-2 program is a joint programme co-funded by the European Union through Horizon 2020 and national funding agencies. The total budget for the project is €1.6M.

Moredun Scientific has already worked with Intervacc to support the initial development of their new vaccine. The Eurostars grant will fund a number of important steps including pre-clinical efficacy studies in piglets, analysis of the immune response and vaccination of pregnant sows. Moredun Scientific will develop new models of S.suis infection during the project which will be added to their portfolio of disease models available for use in client studies.

Streptococcus suis causes severe infections in some pig herds with devastating results for the pig industry. There are almost one billion pigs worldwide and there is a need for an improved vaccine. The proposed new product will be based on recombinant proteins from the bacterial surface used successfully in Intervacc’s vaccine against equine strangles.

John Murray, Managing Director of Moredun Scientific commented “Eurostars funding competitions are highly competitive, we are delighted to be successful with our application which continues our collaboration with Intervacc. The funding award confirms the importance of the S.suis vaccine project and highlights Moredun Scientific’s capabilities and expertise in supporting the development of veterinary vaccines’’.

For more information please contact John Murray, Managing Director Moredun Scientific